Therefore, for patients with ALK-positive NSCLC and BRAF V600-mutant melanoma, HSP90 inhibitor-based combination therapy is a promising strategy to overcome resistance and enhance therapeutic outcomes. This evidence concerns the gene HSP90AA1 and non-small cell lung carcinoma.